Bicycle Therapeutics (BCYC) Net Cash Flow (2018 - 2026)

Bicycle Therapeutics has reported Net Cash Flow for 9 years, with the latest figure at -$66.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 23.36% year-over-year to -$66.7 million; the trailing twelve-month figure through Mar 2026 stood at -$231.8 million (down 169.04% YoY), and the FY2025 full-year result was -$252.2 million, down 171.27% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$66.7 million, down from -$19.9 million in the prior quarter.
• The five-year high for Net Cash Flow was $504.6 million in Q2 2024, with the low at -$87.0 million in Q1 2025.
• Historically, Net Cash Flow has averaged $7.2 million across 5 years, with a median of -$33.1 million in 2022.
• Annual changes were most pronounced in 2022 — Net Cash Flow plunged 1200.46% — and 2023, when it surged 2780.59%.
• Bicycle Therapeutics' Net Cash Flow stood at -$25.9 million in 2022, then slumped by 81.5% to -$47.0 million in 2023, then surged by 79.64% to -$9.6 million in 2024, then plunged by 108.5% to -$19.9 million in 2025, then slumped by 234.55% to -$66.7 million in 2026.
• The last three Net Cash Flow figures came in at -$66.7 million (Q1 2026), -$19.9 million (Q4 2025), and -$71.9 million (Q3 2025), per Business Quant data.